Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
17.07
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
November 18, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
November 14, 2024
From
Meiji Seika Pharma Co., Ltd. and ARCALIS, Inc.
Via
Business Wire
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
November 11, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Unveiling 3 Analyst Insights On Arcturus Therapeutics
October 01, 2024
Via
Benzinga
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
November 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
October 31, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
September 30, 2024
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a...
Via
Benzinga
Exposures
COVID-19
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
September 30, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
September 13, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis
September 03, 2024
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
August 27, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 05, 2024
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
August 05, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
August 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 18, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
July 01, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Cathie Wood-Led Ark Invest Dumps $4.3M Worth Of Nvidia Shares Amid Rebound — Swoops Into Buy Stock Of This Netflix Rival
June 25, 2024
Via
Benzinga
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
June 20, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Cathie Wood-Led Ark Invest Sells $1.5M Worth Of Robinhood Shares Amid Muted Bitcoin Market — Also Dumps Zoom Stock Worth $3.3M
June 12, 2024
Ark Invest, led by Cathie Wood, made significant trades on Wednesday involving Robinhood Markets Inc (NASDAQ:HOOD) and Zoom Video Communications Inc (NASDAQ:ZM).
Via
Benzinga
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
June 10, 2024
On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...
Via
Benzinga
Arcturus' Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
June 07, 2024
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 07, 2024
Via
Benzinga
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
June 07, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics' Early Cystic Fibrosis Trial Results Encouraging - Analyst Cautiously Optimistic
May 28, 2024
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.
Via
Benzinga
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
May 28, 2024
Via
Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 28, 2024
Via
Benzinga
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
May 28, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024
From
Achilles Therapeutics PLC
Via
GlobeNewswire
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COVID-19 Vaccine
May 20, 2024
From
Arcturus Therapeutics
Via
Business Wire
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
May 15, 2024
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.